Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has received an average rating of “Buy” from the nine ratings firms that are covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $27.00.

A number of analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 21st. BidaskClub upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 price objective on shares of Kalvista Pharmaceuticals in a research note on Friday, December 14th.

NASDAQ:KALV opened at $31.10 on Friday. The firm has a market capitalization of $411.35 million, a PE ratio of -20.33 and a beta of 2.45. Kalvista Pharmaceuticals has a 1-year low of $7.73 and a 1-year high of $34.92.

Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 84.47% and a negative return on equity of 29.46%. Research analysts forecast that Kalvista Pharmaceuticals will post -1.65 EPS for the current fiscal year.

In related news, CEO Thomas Andrew Crockett sold 10,000 shares of the firm’s stock in a transaction on Monday, January 14th. The shares were sold at an average price of $19.33, for a total transaction of $193,300.00. Following the sale, the chief executive officer now owns 272,411 shares in the company, valued at $5,265,704.63. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Christopher Yea sold 1,902 shares of the firm’s stock in a transaction on Wednesday, January 23rd. The shares were sold at an average price of $17.01, for a total transaction of $32,353.02. Following the sale, the insider now owns 84,271 shares in the company, valued at approximately $1,433,449.71. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 314,718 shares of company stock worth $6,509,410. 38.40% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in KALV. VHCP Management III LLC acquired a new stake in Kalvista Pharmaceuticals during the third quarter valued at $28,410,000. Vivo Capital LLC grew its position in Kalvista Pharmaceuticals by 352.6% during the third quarter. Vivo Capital LLC now owns 1,359,149 shares of the specialty pharmaceutical company’s stock valued at $30,051,000 after buying an additional 1,058,824 shares during the period. VHCP Management II LLC acquired a new stake in Kalvista Pharmaceuticals during the third quarter valued at $16,785,000. Vanguard Group Inc grew its position in Kalvista Pharmaceuticals by 152.4% during the third quarter. Vanguard Group Inc now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after buying an additional 179,092 shares during the period. Finally, Vanguard Group Inc. grew its position in Kalvista Pharmaceuticals by 152.4% during the third quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after buying an additional 179,092 shares during the period. Institutional investors own 77.31% of the company’s stock.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: Cryptocurrencies

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.